drugset / Trial / NCT05180461

Emodepside Phase II Trial for Treatment of Onchocerciasis

NCT05180461

Phase 2 Active not recruiting 578 enrolled Drugs for Neglected Diseases Bayer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.

Timeline

Start
2021-08-30
Primary completion
2026-09-18
Completion
2026-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Emodepside Small molecule 15 mg
Subject Emodepside Small molecule 30 mg
Comparator Ivermectin Small molecule 150 ug/kg Oral

Indications